DailySand tracks Drug trials across AI, semiconductor infrastructure, capital markets, and critical minerals supply chains. Below are curated source items and daily digests where Drug trials appears in today's cross-sector intelligence briefing.
1 item across 1 digest
Novartis shares fell 10% following disappointing results from its del-desiran drug trial. Failed late-stage trial results directly impact investor confidence and reduce the company's future revenue pipeline.
Read original →
DailySand